Time filter

Source Type

Kurosawa M.,Sutoh Hospital | Kurosawa M.,Gunma Institute for Allergy and Asthma | Yukawa T.,Yukawa Clinic of Internal Medicine | Hozawa S.,Hiroshima Allergy and Respiratory Clinic | Mochizuki H.,Tokai University
Allergologia et Immunopathologia | Year: 2015

Aspirin-exacerbated respiratory disease (AERD) is a complex clinical syndrome characterised by severe asthmatic attack upon treatment with aspirin and/or non-steroidal anti-inflammatory drugs (NSAIDs). Genetic predisposition has been considered as a crucial determinant and candidate genes have concentrated especially on cysteinyl leukotrienes (LTs)-related genes as the inhibitory action of aspirin and NSAIDs on cyclooxygenase activity may cause overproduction of cysteinyl LTs. However, conflicting results have been reported, in parallel with replication studies in different ethnic groups. Thus, future areas of investigations need to focus on comprehensive approaches towards the discovery of other genetic biomarkers. Unfortunately, few papers have been reported about gene polymorphisms in Japanese patients with AERD. Here, we described on our recent genetic investigations on B2ADR, IL-13, IL-17A, CYP2C19, TBXA2R, CRTH2 and HSP70. This review indicates potential genetic biomarkers contributing to the early diagnosis of AERD, which may include CYP2C19 and HSP70 gene polymorphisms, and future validation studies in independent population are required to provide reassurance about our findings. © 2014 SEICAP.

Loading Gunma Institute for Allergy and Asthma collaborators
Loading Gunma Institute for Allergy and Asthma collaborators